BRAIN BIOTECH AG (BNN.DE) Fundamental Analysis & Valuation

FRA:BNN • DE0005203947

Current stock price

2.55 EUR
+0.05 (+2%)
Last:

This BNN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BNN.DE Profitability Analysis

1.1 Basic Checks

  • BNN had negative earnings in the past year.
  • BNN had a negative operating cash flow in the past year.
  • In the past 5 years BNN always reported negative net income.
  • In the past 5 years BNN always reported negative operating cash flow.
BNN.DE Yearly Net Income VS EBIT VS OCF VS FCFBNN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • With a Return On Assets value of -15.88%, BNN is not doing good in the industry: 81.16% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -15.88%
ROE N/A
ROIC N/A
ROA(3y)-13.97%
ROA(5y)-11.35%
ROE(3y)-254.67%
ROE(5y)-159.82%
ROIC(3y)N/A
ROIC(5y)N/A
BNN.DE Yearly ROA, ROE, ROICBNN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • With an excellent Gross Margin value of 59.16%, BNN belongs to the best of the industry, outperforming 86.96% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BNN has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for BNN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.36%
BNN.DE Yearly Profit, Operating, Gross MarginsBNN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BNN.DE Health Analysis

2.1 Basic Checks

  • BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BNN remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, BNN has more shares outstanding
  • Compared to 1 year ago, BNN has a worse debt to assets ratio.
BNN.DE Yearly Shares OutstandingBNN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
BNN.DE Yearly Total Debt VS Total AssetsBNN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.88%
BNN.DE Yearly LT Debt VS Equity VS FCFBNN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M 40M

2.3 Liquidity

  • BNN has a Current Ratio of 1.48. This is a normal value and indicates that BNN is financially healthy and should not expect problems in meeting its short term obligations.
  • BNN has a Current ratio (1.48) which is comparable to the rest of the industry.
  • BNN has a Quick Ratio of 1.48. This is a normal value and indicates that BNN is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of BNN (1.48) is better than 71.01% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.48
BNN.DE Yearly Current Assets VS Current LiabilitesBNN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BNN.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.13% over the past year.
  • BNN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.20%.
  • BNN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.15% yearly.
EPS 1Y (TTM)15.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
Revenue 1Y (TTM)-12.2%
Revenue growth 3Y-0.05%
Revenue growth 5Y5.15%
Sales Q2Q%-9.11%

3.2 Future

  • BNN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.84% yearly.
  • The Revenue is expected to grow by 7.06% on average over the next years.
EPS Next Y-77.84%
EPS Next 2Y17.53%
EPS Next 3Y-5.84%
EPS Next 5YN/A
Revenue Next Year-11.79%
Revenue Next 2Y4.07%
Revenue Next 3Y1.58%
Revenue Next 5Y7.06%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BNN.DE Yearly Revenue VS EstimatesBNN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M 100M
BNN.DE Yearly EPS VS EstimatesBNN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. BNN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BNN. In the last year negative earnings were reported.
  • Also next year BNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNN.DE Price Earnings VS Forward Price EarningsBNN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNN.DE Per share dataBNN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as BNN's earnings are expected to decrease with -5.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.53%
EPS Next 3Y-5.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNN.DE Dividend Analysis

5.1 Amount

  • No dividends for BNN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNN.DE Fundamentals: All Metrics, Ratios and Statistics

BRAIN BIOTECH AG

FRA:BNN (4/20/2026, 4:16:41 PM)

2.55

+0.05 (+2%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-25
Earnings (Next)05-28
Inst Owners8.22%
Inst Owner ChangeN/A
Ins Owners52.2%
Ins Owner ChangeN/A
Market Cap55.72M
Revenue(TTM)49.01M
Net Income(TTM)-10.62M
Analysts85
Price Target5.36 (110.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.19%
PT rev (3m)-12.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-27.78%
EPS NY rev (3m)-84.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-9.5%
Revenue NY rev (3m)-21.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS2.24
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -15.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.16%
FCFM N/A
ROA(3y)-13.97%
ROA(5y)-11.35%
ROE(3y)-254.67%
ROE(5y)-159.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.36%
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.48
Altman-Z N/A
F-Score4
WACC6.88%
ROIC/WACCN/A
Cap/Depr(3y)41.29%
Cap/Depr(5y)59.09%
Cap/Sales(3y)3.67%
Cap/Sales(5y)5.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
EPS Next Y-77.84%
EPS Next 2Y17.53%
EPS Next 3Y-5.84%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.2%
Revenue growth 3Y-0.05%
Revenue growth 5Y5.15%
Sales Q2Q%-9.11%
Revenue Next Year-11.79%
Revenue Next 2Y4.07%
Revenue Next 3Y1.58%
Revenue Next 5Y7.06%
EBIT growth 1Y37.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3Y143.85%
EBIT Next 5YN/A
FCF growth 1Y-28.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.03%
OCF growth 3YN/A
OCF growth 5YN/A

BRAIN BIOTECH AG / BNN.DE Fundamental Analysis FAQ

What is the fundamental rating for BNN stock?

ChartMill assigns a fundamental rating of 2 / 10 to BNN.DE.


What is the valuation status for BNN stock?

ChartMill assigns a valuation rating of 0 / 10 to BRAIN BIOTECH AG (BNN.DE). This can be considered as Overvalued.


What is the profitability of BNN stock?

BRAIN BIOTECH AG (BNN.DE) has a profitability rating of 1 / 10.


How financially healthy is BRAIN BIOTECH AG?

The financial health rating of BRAIN BIOTECH AG (BNN.DE) is 2 / 10.